|1.||Vijay, Nisha: 1 article (06/2015)|
|2.||Morse, Bridget L: 1 article (06/2015)|
|3.||Morris, Marilyn E: 1 article (06/2015)|
|4.||Seront, Emmanuel: 1 article (06/2014)|
|5.||Bouzin, Caroline: 1 article (06/2014)|
|6.||Draoui, Nihed: 1 article (06/2014)|
|7.||Feron, Olivier: 1 article (06/2014)|
|8.||Schicke, Olivier: 1 article (06/2014)|
|9.||Sonveaux, Pierre: 1 article (06/2014)|
|10.||Riant, Olivier: 1 article (06/2014)|
|1.||Respiratory Insufficiency (Respiratory Failure)
06/01/2014 - "Finally, we found that contrary to AR-C155858, 7ACC did not prevent the cell entry of the substrate-mimetic drug 3-bromopyruvate (3BP) through MCT1, and contributed to the inhibition of tumor relapse after 3BP treatment. "
06/01/2014 - "Contrary to the reference MCT1 inhibitor AR-C155858, 7ACC unexpectedly inhibited lactate influx but not efflux in tumor cells expressing MCT1 and MCT4 transporters. "
03/15/2012 - "Similarly, we discuss how stromal MCT4 could be used as a biomarker for identifying high-risk cancer patients that could likely benefit from treatment with FDA-approved drugs or existing MCT-inhibitors (such as, AR-C155858, AR-C117977, and AZD-3965)."
10/04/2011 - "First, we showed that blocking MCT1/2 in Ras-transformed fibroblasts with AR-C155858 suppressed lactate export, glycolysis, and tumor growth, whereas ectopic expression of MCT4 in these cells conferred resistance to MCT1/2 inhibition and reestablished tumorigenicty. "